Phase III Randomized Double masked Multicenter Active controlled Study to Evaluate the Efficacy and Safety of Two Different Dosing Regimens of 0 5 mg Ranibizumab vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia Sponsor Novartis Pharmaceuticals CRFB002F2301 , ARAŞTIRMA PROJESİ, Araştırmacı, 2010-2014)